INAVA-ARNO complexes bridge mucosal barrier function with inflammatory signaling

  1. Phi H Luong
  2. Matija Hedl
  3. Jie Yan
  4. Tao Zuo
  5. Tian-Min Fu
  6. Xiaomo Jiang
  7. Jay R Thiagarajah
  8. Steen H Hansen
  9. Cammie F Lesser
  10. Hao Wu
  11. Clara Abraham
  12. Wayne I Lencer  Is a corresponding author
  1. Harvard Medical School, United States
  2. Yale University, United States
  3. Novartis Institutes for Biomedical Research, United States
  4. Massachusetts General Hospital, United States

Abstract

Homeostasis at mucosal surfaces requires cross-talk between the environment and barrier epithelial cells. Disruption of barrier function typifies mucosal disease. Here we elucidate a bifunctional role in coordinating this cross-talk for the inflammatory bowel disease risk-gene INAVA. Both activities require INAVA's DUF3338 domain (renamed CUPID). CUPID stably binds the cytohesin ARF-GEF ARNO to effect lateral membrane F-actin assembly underlying cell-cell junctions and barrier function. Unexpectedly, when bound to CUPID, ARNO affects F-actin dynamics in the absence of its canonical activity as a guanine nucleotide-exchange factor. Upon exposure to IL-1β, INAVA relocates to form cytosolic puncta, where CUPID amplifies TRAF6-dependent polyubiquitination and inflammatory signaling. In this case, ARNO binding to CUPID negatively-regulates polyubiquitination and the inflammatory response. INAVA and ARNO act similarly in primary human macrophages responding to IL-1β and NOD2 agonists. Thus, INAVA-CUPID exhibits dual functions, coordinated directly by ARNO, that bridge epithelial barrier function with extracellular signals and inflammation.

Data availability

All data analysed during this study are included in the manuscript. Source data have been provided for Figure 3 C-F.

Article and author information

Author details

  1. Phi H Luong

    Department of Pediatrics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  2. Matija Hedl

    Department of Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  3. Jie Yan

    Department of Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  4. Tao Zuo

    Department of Pediatrics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  5. Tian-Min Fu

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  6. Xiaomo Jiang

    Novartis Institutes for Biomedical Research, Cambridge, United States
    Competing interests
    Xiaomo Jiang, is affiliated with Novartis. The author has no other competing interests to declare.
  7. Jay R Thiagarajah

    Department of Pediatrics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  8. Steen H Hansen

    Department of Pediatrics, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  9. Cammie F Lesser

    Department of Medicine, Division of Infectious Diseases, Massachusetts General Hospital, Cambridge, United States
    Competing interests
    No competing interests declared.
  10. Hao Wu

    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
  11. Clara Abraham

    Department of Medicine, Yale University, New Haven, United States
    Competing interests
    No competing interests declared.
  12. Wayne I Lencer

    Department of Pediatrics, Harvard Medical School, Boston, United States
    For correspondence
    Wayne.Lencer@childrens.harvard.edu
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-7346-2730

Funding

National Institutes of Health (T32HD007466)

  • Phi H Luong

Crohn's and Colitis Foundation of America (Career Development Award)

  • Phi H Luong

Boston Children's Hospital (Rubin-Wolpow Fellowship)

  • Phi H Luong

National Institutes of Health (DK099097)

  • Clara Abraham

National Institutes of Health (DK048106)

  • Wayne I Lencer

National Institutes of Health (DK084424)

  • Wayne I Lencer

National Institutes of Health (P30 DK034854)

  • Wayne I Lencer

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Kiyoshi Takeda, Osaka University, Japan

Version history

  1. Received: May 21, 2018
  2. Accepted: October 15, 2018
  3. Accepted Manuscript published: October 25, 2018 (version 1)
  4. Version of Record published: November 9, 2018 (version 2)

Copyright

© 2018, Luong et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,441
    views
  • 261
    downloads
  • 16
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Phi H Luong
  2. Matija Hedl
  3. Jie Yan
  4. Tao Zuo
  5. Tian-Min Fu
  6. Xiaomo Jiang
  7. Jay R Thiagarajah
  8. Steen H Hansen
  9. Cammie F Lesser
  10. Hao Wu
  11. Clara Abraham
  12. Wayne I Lencer
(2018)
INAVA-ARNO complexes bridge mucosal barrier function with inflammatory signaling
eLife 7:e38539.
https://doi.org/10.7554/eLife.38539

Share this article

https://doi.org/10.7554/eLife.38539

Further reading

    1. Biochemistry and Chemical Biology
    2. Neuroscience
    Maximilian Nagel, Marco Niestroj ... Marc Spehr
    Research Article

    In most mammals, conspecific chemosensory communication relies on semiochemical release within complex bodily secretions and subsequent stimulus detection by the vomeronasal organ (VNO). Urine, a rich source of ethologically relevant chemosignals, conveys detailed information about sex, social hierarchy, health, and reproductive state, which becomes accessible to a conspecific via vomeronasal sampling. So far, however, numerous aspects of social chemosignaling along the vomeronasal pathway remain unclear. Moreover, since virtually all research on vomeronasal physiology is based on secretions derived from inbred laboratory mice, it remains uncertain whether such stimuli provide a true representation of potentially more relevant cues found in the wild. Here, we combine a robust low-noise VNO activity assay with comparative molecular profiling of sex- and strain-specific mouse urine samples from two inbred laboratory strains as well as from wild mice. With comprehensive molecular portraits of these secretions, VNO activity analysis now enables us to (i) assess whether and, if so, how much sex/strain-selective ‘raw’ chemical information in urine is accessible via vomeronasal sampling; (ii) identify which chemicals exhibit sufficient discriminatory power to signal an animal’s sex, strain, or both; (iii) determine the extent to which wild mouse secretions are unique; and (iv) analyze whether vomeronasal response profiles differ between strains. We report both sex- and, in particular, strain-selective VNO representations of chemical information. Within the urinary ‘secretome’, both volatile compounds and proteins exhibit sufficient discriminative power to provide sex- and strain-specific molecular fingerprints. While total protein amount is substantially enriched in male urine, females secrete a larger variety at overall comparatively low concentrations. Surprisingly, the molecular spectrum of wild mouse urine does not dramatically exceed that of inbred strains. Finally, vomeronasal response profiles differ between C57BL/6 and BALB/c animals, with particularly disparate representations of female semiochemicals.

    1. Biochemistry and Chemical Biology
    2. Structural Biology and Molecular Biophysics
    Claudia D Consalvo, Adedeji M Aderounmu ... Brenda L Bass
    Research Article

    Invertebrates use the endoribonuclease Dicer to cleave viral dsRNA during antiviral defense, while vertebrates use RIG-I-like Receptors (RLRs), which bind viral dsRNA to trigger an interferon response. While some invertebrate Dicers act alone during antiviral defense, Caenorhabditis elegans Dicer acts in a complex with a dsRNA binding protein called RDE-4, and an RLR ortholog called DRH-1. We used biochemical and structural techniques to provide mechanistic insight into how these proteins function together. We found RDE-4 is important for ATP-independent and ATP-dependent cleavage reactions, while helicase domains of both DCR-1 and DRH-1 contribute to ATP-dependent cleavage. DRH-1 plays the dominant role in ATP hydrolysis, and like mammalian RLRs, has an N-terminal domain that functions in autoinhibition. A cryo-EM structure indicates DRH-1 interacts with DCR-1’s helicase domain, suggesting this interaction relieves autoinhibition. Our study unravels the mechanistic basis of the collaboration between two helicases from typically distinct innate immune defense pathways.